The 6 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 17.00, with a high estimate of 25.00 and a low estimate of 3.00. The median estimate represents a +908.90% increase from the last price of 1.69.
The current consensus among 6 polled investment analysts is to Buy stock in Cara Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.51
Reporting Date Nov 07
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.